METADATE ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METADATE ER (METADATE ER).
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid. Minor pathways include oxidative metabolism via CYP2D6. The drug undergoes extensive first-pass metabolism. |
| Excretion | Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination. |
| Half-life | Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation. |
| Protein binding | 10-33% (primarily albumin). |
| Volume of Distribution | Vd: 2-4 L/kg; indicates extensive tissue distribution and penetration into the central nervous system. |
| Bioavailability | Oral: 30% (due to first-pass metabolism); Metadate ER: similar to immediate-release with extended dissolution profile. |
| Onset of Action | Oral immediate-release: 30-60 minutes; extended-release (Metadate ER): 1-2 hours. |
| Duration of Action | Metadate ER: approximately 8 hours (due to biphasic release); clinical note: effects may vary with individual metabolism. |
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (eGFR <30 mL/min/1.73m²) and consider dose reduction based on tolerability. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Not recommended. |
| Pediatric use | Age ≥6 years: Initial 10-20 mg orally once daily; increase by 10 mg weekly. Maximum: 60 mg/day or 2 mg/kg/day, whichever is less. |
| Geriatric use | Initiate at lower doses (e.g., 10 mg once daily) with cautious titration due to increased sensitivity and higher risk of adverse effects such as hypertension, agitation, and insomnia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for METADATE ER (METADATE ER).
| Breastfeeding | Methylphenidate is excreted into breast milk in low concentrations (M/P ratio approximately 2.5). Short-term use is considered compatible with breastfeeding; however, observe infant for agitation, insomnia, and reduced weight gain. Avoid long-acting formulations due to higher milk concentrations. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (including irritability, dysphoria, and feeding difficulties). |
■ FDA Black Box Warning
METADATE ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Physicians should assess the risk of abuse before prescribing and monitor for signs of abuse during therapy.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the formulation","Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy","Glaucoma","Hyperthyroidism or thyrotoxicosis","Tics or family history of Tourette's syndrome","Severe hypertension or other cardiovascular conditions","History of drug abuse or dependence"]
| Precautions | ["Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems","Increased blood pressure and heart rate","Psychiatric adverse reactions including exacerbation of pre-existing psychosis, mania, or aggression","Seizures in patients with history of seizure disorders","Long-term suppression of growth in children","Potential for peripheral vasculopathy including Raynaud's phenomenon","Serotonin syndrome when used with serotonergic drugs","Hematologic effects such as leukopenia and thrombocytopenia"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly; assess for symptoms of preeclampsia. Fetal ultrasound to monitor growth and amniotic fluid volume. Neonatal monitoring for withdrawal symptoms and appropriate weight gain after delivery. |
| Fertility Effects | No known adverse effects on fertility in animal studies; limited human data. May improve fertility in women with ADHD by enhancing treatment adherence and reducing impulsive behaviors. |